Denali TherapeuticsDNLI
Market Cap: $3.61B
About: Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Employees: 364
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
119% more call options, than puts
Call options by funds: $4.24M | Put options by funds: $1.93M
41% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 59
15% more capital invested
Capital invested by funds: $2.42B [Q1] → $2.78B (+$362M) [Q2]
0.71% less ownership
Funds ownership: 84.57% [Q1] → 83.86% (-0.71%) [Q2]
2% less funds holding
Funds holding: 205 [Q1] → 200 (-5) [Q2]
14% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 36
50% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 2 (-2) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 77 / 166 met price target | 256%upside $90 | Buy Reiterated | 4 Sept 2024 |
B of A Securities Tazeen Ahmad 57% 1-year accuracy 13 / 23 met price target | 15%upside $29 | Buy Maintained | 4 Sept 2024 |
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 77 / 166 met price target | 256%upside $90 | Buy Reiterated | 15 Aug 2024 |
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 77 / 166 met price target | 256%upside $90 | Buy Maintained | 5 Aug 2024 |
Citigroup David Hoang 67% 1-year accuracy 14 / 21 met price target | 27%upside $32 | Buy Maintained | 2 Aug 2024 |
Financial journalist opinion
Based on 4 articles about DNLI published over the past 30 days